药学与临床研究
藥學與臨床研究
약학여림상연구
PHARMACEUTICAL AND CLINICAL RESEARCH
2015年
3期
267-270
,共4页
鞠晓宇%罗雪梅%葛卫红%王友群
鞠曉宇%囉雪梅%葛衛紅%王友群
국효우%라설매%갈위홍%왕우군
伊立替康%SN-38%血药浓度%高效液相色谱%荧光检测
伊立替康%SN-38%血藥濃度%高效液相色譜%熒光檢測
이립체강%SN-38%혈약농도%고효액상색보%형광검측
Irinotecan%SN-38%Plasma concentration%HPLC%Fluorescence detector
目的：建立高效液相色谱法同时测定结直肠癌患者血中的伊立替康（CPT-11）及其活性代谢物7-乙基-10-羟基喜树碱（SN-38）的浓度，并对我院基因型指导给药方案进行评价。方法：以2μg·mL-110-羟基喜树碱作为内标，先用100μL 10%高氯酸沉淀蛋白，再用50μL 10%高氯酸酸化血浆。采用Agilent ZORBAX Eclipse C8色谱柱（4.6 mm×150 mm，5μm）对CPT-11和SN-38进行分离；以0.05 mol·L-1的磷酸二氢钠-乙腈-三乙胺（75∶25∶0.1，v∶v，磷酸调pH 3.0）为流动相；荧光检测波长：激发波长380 nm，发射波长550 nm。结果：人血浆中CPT-11和SN-38线性范围均为3~1000 ng·mL-1，定量下限为3 ng·mL-1；准确度分别是98.5%和100.0%；回收率分别是83.8%和84.3%。结论：本方法可靠、简便、快速，可为伊立替康个体化给药提供参考。
目的：建立高效液相色譜法同時測定結直腸癌患者血中的伊立替康（CPT-11）及其活性代謝物7-乙基-10-羥基喜樹堿（SN-38）的濃度，併對我院基因型指導給藥方案進行評價。方法：以2μg·mL-110-羥基喜樹堿作為內標，先用100μL 10%高氯痠沉澱蛋白，再用50μL 10%高氯痠痠化血漿。採用Agilent ZORBAX Eclipse C8色譜柱（4.6 mm×150 mm，5μm）對CPT-11和SN-38進行分離；以0.05 mol·L-1的燐痠二氫鈉-乙腈-三乙胺（75∶25∶0.1，v∶v，燐痠調pH 3.0）為流動相；熒光檢測波長：激髮波長380 nm，髮射波長550 nm。結果：人血漿中CPT-11和SN-38線性範圍均為3~1000 ng·mL-1，定量下限為3 ng·mL-1；準確度分彆是98.5%和100.0%；迴收率分彆是83.8%和84.3%。結論：本方法可靠、簡便、快速，可為伊立替康箇體化給藥提供參攷。
목적：건립고효액상색보법동시측정결직장암환자혈중적이립체강（CPT-11）급기활성대사물7-을기-10-간기희수감（SN-38）적농도，병대아원기인형지도급약방안진행평개。방법：이2μg·mL-110-간기희수감작위내표，선용100μL 10%고록산침정단백，재용50μL 10%고록산산화혈장。채용Agilent ZORBAX Eclipse C8색보주（4.6 mm×150 mm，5μm）대CPT-11화SN-38진행분리；이0.05 mol·L-1적린산이경납-을정-삼을알（75∶25∶0.1，v∶v，린산조pH 3.0）위류동상；형광검측파장：격발파장380 nm，발사파장550 nm。결과：인혈장중CPT-11화SN-38선성범위균위3~1000 ng·mL-1，정량하한위3 ng·mL-1；준학도분별시98.5%화100.0%；회수솔분별시83.8%화84.3%。결론：본방법가고、간편、쾌속，가위이립체강개체화급약제공삼고。
Objective: To determine irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) in plasma of patients with colorectal cancer by high performance liquid chromatography coupled with fluorescence detection and to evaluate the dosage regimen by genotype information. Methods:Irinotecan and metabolites were detected in plasma. The internal standard was 2μg·mL-1 10-hydroxycamp-tothecin. Protein in plasma was precipitated with 10% perchloric acid before acidification with 10% perchloric acid. Separation of the compounds was achieved using an Agilent ZORBAX Eclipse C8 (4.6 mm×150 mm, 5μm) analytical column. The elution was performed with a mobile phase of 0.05 mol·L-1 sodium dihydrogen phosphate solution -acetonitrile (75∶25, v∶v) containing 0.1% triethylamine. The fluorescence detector excitation and emis-sion wavelengths were set at 380 and 550 nm, respectively. Results: The linear ranges for CPT-11 and SN-38 were 3-1000 ng·mL-1. The limits of quantification of CPT-11 and SN-38 were 3 ng·mL-1. The average accuracy of CPT-11 and SN-38 were 98.5% and 100.0%; the average recoveries were 83.8% and 84.3%. Conclusion: This method is reliable, convenient and efficient, which can provide reference for individualized drug administration.
